Insider · CIK 0001702031

Birznieks Gunther

Reports to the SEC for 1 company · WASHINGTON, DC

sec.gov

Transactions

Companies

Filings

CIK

0001702031

Forms 4 and 5

Insider transactions

37 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-02	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−42.4K sh	$8.27	−$351K	494,197
2026-02-18	VNDAVanda Pharmaceuticals Inc.A Award	SVP, Business Development	AAward	+125K sh	—	—	536,628
2025-03-01	VNDAVanda Pharmaceuticals Inc.F Tax Payment	SVP, Business Development	FTax Payment	−26.9K sh	$4.76	−$128K	411,628
2025-02-18	VNDAVanda Pharmaceuticals Inc.A Award	SVP, Business Development	AAward	+125K sh	—	—	438,569
2024-03-05	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−8,684 sh	$4.13	−$35.9K	313,569
2024-03-04	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−8,727 sh	$4.30	−$37.5K	322,253
2024-02-16	VNDAVanda Pharmaceuticals Inc.A Award	SVP, Business Development	AAward	+125K sh	—	—	330,980
2023-03-03	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−8,268 sh	$6.26	−$51.8K	205,980
2023-03-02	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−8,509 sh	$6.20	−$52.8K	214,248
2023-02-16	VNDAVanda Pharmaceuticals Inc.A Award	SVP, Business Development	AAward	+32.7K sh	—	—	222,757
2023-02-16	VNDAVanda Pharmaceuticals Inc. · Stock Option (Right to Buy)A Award	SVP, Business Development	AAward	+77.5K sh	—	—	77,500
2022-08-26	VNDAVanda Pharmaceuticals Inc.M Exercise/Conversion	SVP, Business Development	MExercise/Conversion	+1,250 sh	$3.12	+$3,900	190,057
2022-08-26	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)M Exercise/Conversion	SVP, Business Development	MExercise/Conversion	−1,250 sh	—	—	0
2022-03-02	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−11.5K sh	$11.27	−$130K	188,807
2022-03-01	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−4,084 sh	$11.19	−$45.7K	200,324
2022-02-28	VNDAVanda Pharmaceuticals Inc.A Award	SVP, Business Development	AAward	+32.7K sh	—	—	204,408
2022-02-28	VNDAVanda Pharmaceuticals Inc. · Stock Option (Right to Buy)A Award	SVP, Business Development	AAward	+77.5K sh	—	—	77,500
2021-03-02	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−16.6K sh	$18.19	−$302K	171,708
2021-03-01	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−3,845 sh	$18.66	−$71.7K	188,328
2021-02-24	VNDAVanda Pharmaceuticals Inc.A Award	SVP, Business Development	AAward	+32.7K sh	—	—	192,173
2021-02-24	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)A Award	SVP, Business Development	AAward	+77.5K sh	—	—	77,500
2020-03-03	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−5,535 sh	$10.66	−$59K	159,473
2020-03-02	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−12.2K sh	$10.04	−$123K	165,008
2020-02-26	VNDAVanda Pharmaceuticals Inc.A Award	SVP, Business Development	AAward	+30K sh	—	—	177,231
2020-02-26	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)A Award	SVP, Business Development	AAward	+70K sh	—	—	70,000
2020-01-02	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−4,020 sh	$15.93	−$64K	147,231
2019-03-04	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−8,788 sh	$19.89	−$175K	151,251
2019-03-01	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−3,741 sh	$20.14	−$75.3K	160,039
2019-02-27	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)A Award	SVP, Business Development	AAward	+70K sh	—	—	70,000
2019-02-27	VNDAVanda Pharmaceuticals Inc.A Award	SVP, Business Development	AAward	+30K sh	—	—	163,780
2019-01-03	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−1,619 sh	$26.09	−$42.2K	133,780
2019-01-02	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−1,170 sh	$26.95	−$31.5K	135,399
2019-01-02	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−3,272 sh	$26.30	−$86.1K	136,569
2018-03-01	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−8,525 sh	$18.72	−$160K	139,841
2018-02-28	VNDAVanda Pharmaceuticals Inc. · Employee Stock Option (Right to Buy)A Award	SVP, Business Development	AAward	+70K sh	—	—	70,000
2018-02-28	VNDAVanda Pharmaceuticals Inc.A Award	SVP, Business Development	AAward	+30K sh	—	—	148,366
2018-01-02	VNDAVanda Pharmaceuticals Inc.S Sale	SVP, Business Development	SSale	−8,568 sh	$15.26	−$131K	118,366

Recent filings

Accepted (ET)
Mar 44
Birznieks Gunther0001702031-26-000002
SEC(opens sec.gov)
Feb 194
Birznieks Gunther0001193125-26-059784
SEC(opens sec.gov)
Mar 44
Birznieks Gunther0000950170-25-032281
SEC(opens sec.gov)
Feb 204
Birznieks Gunther0000950170-25-024486
SEC(opens sec.gov)
Mar 64
Birznieks Gunther0000950170-24-027249
SEC(opens sec.gov)
Feb 214
Birznieks Gunther0000950170-24-018024
SEC(opens sec.gov)
Mar 64
Birznieks Gunther0001209191-23-016460
SEC(opens sec.gov)
Feb 214
Birznieks Gunther0001209191-23-011338
SEC(opens sec.gov)
Aug 294
Birznieks Gunther0001209191-22-047887
SEC(opens sec.gov)
Mar 24
Birznieks Gunther0001209191-22-015154
SEC(opens sec.gov)
Mar 34
Birznieks Gunther0001209191-21-017272
SEC(opens sec.gov)
Feb 264
Birznieks Gunther0001209191-21-014869
SEC(opens sec.gov)

Companies

Vanda Pharmaceuticals Inc.SVP, Business DevelopmentVNDA

Address

2200 PENNSYLVANIA AVENUE NW SUITE 300E

WASHINGTON, DC, 20037